26 February 2024 in Obesity Reviews
1 September 2021 in Toxicology
30 October 2024 in Endocrinology
Although it is known that prenatal maternal stress (PNMS) has a negative influence on nervous system development in offspring, there is no conclusive evidence clarifying its impact on early neurogenesis during development. In this study, we established a chick embryo model to investigate how PNMS affects early neurogenesis by mimicking an intrauterine environment with elevated dexamethasone levels. The results showed that dexamethasone-mimicked PNMS significantly suppressed the development of gastrula embryos and increased the risks of neural tube defects and cranial deformity. Using immunofluorescence staining and Western blots to evaluate the expression levels of pHIS3 and PCNA/Sox2, we found that PNMS significantly inhibited the proliferation of neural progenitor cells and that the downregulation of TGF-β signaling pathway might be responsible for the inhibition. Furthermore, immunofluorescence staining and Western blots manifested that PNMS could suppress the differentiation of neural progenitor cells to neuronal lineages, but promote them to transform into neuroglial cells, which might be due to the restriction of expressions of key genes (BMP4, SHH, Wnt3a, Slug, and Msx1) related to neural differentiation. In summary, our data reveal that PNMS dramatically impacts the earliest stages of neural development, thereby greatly increasing the risk of physical and mental health problems in childhood or adulthood.
22 August 2025 in Aesthetic Surgery Journal
Background: Capsular contracture remains a prevalent complication following breast implant augmentation. Despite growing interest in pharmacological prevention, optimal drug selection and administration timing remain unclear. Objectives: The authors of this study aim to compare the efficacy of tranilast vs montelukast and evaluate prophylactic vs postoperative administration in preventing capsular contracture. Methods: Eighty male C57BL/6J mice were randomized into 5 groups: control, post-montelukast, pre-montelukast, post-tranilast, and pre-tranilast. For 1 preoperative month, the control group received daily saline (1 mL) through gavage, whereas drug-treated groups received montelukast (10 mg/kg/day) or tranilast (50 mg/kg/day). Prophylactic groups initiated drug administration preoperatively. Miniature implants were bilaterally placed dorsally, followed by 3 months of postoperative drug continuation. Histopathological evaluation assessed capsule thickness, macrophage infiltration, collagen density, and inflammatory response. Results: At 90 days post surgery, all drug interventions significantly reduced capsular thickness compared with the control group (control: 232.4 ± 43 μm; post-montelukast: 137.5 ± 24 μm; pre-montelukast: 107.7 ± 20 μm; post-tranilast: 93.3 ± 22 μm; pre-tranilast: 70.2 ± 11 μm; P < .0001). The pre-tranilast group demonstrated the lowest collagen deposition at 90 days (16.0 ± 5% vs control: 76.6 ± 13%; P < .001). Pre-tranilast exhibited superior macrophage inhibitory effects compared with post-tranilast administration. Furthermore, tranilast outperformed montelukast in efficacy regardless of administration timing. Conclusions: Prophylactic tranilast administration significantly attenuates capsular contracture by reducing inflammation, macrophage infiltration, and collagen deposition, surpassing both postoperative tranilast and montelukast. These findings support prioritizing preoperative tranilast in clinical trials to improve breast implant outcomes.